FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:76-77 January 3, 2008 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

This spring the Supreme Court of the United States will decide whether premarketing approval of a medical device by the Food and Drug Administration (FDA) immunizes the manufacturer against product-liability litigation in state courts. This decision, we believe, is a matter of particular importance to patients and the medical community.

On December 4, 2007, the Supreme Court heard oral arguments in Riegel v. Medtronic.¹ In May 1996, Charles Riegel underwent coronary angioplasty in Albany, New York. During the procedure, the balloon ruptured, and advanced cardiac life support and emergency coronary bypass surgery were needed. Mr. Riegel and his wife . . . [Full Text of this Article]

Related Letters:

A Pivotal Medical-Device Case
Greenspan H., Picca S. M., Sonder G.
Extract | Full Text | PDF  
N Engl J Med 2008; 358:1758, Apr 17, 2008. Correspondence

This article has been cited by other articles:

• Cooney, W. P. III (2008). The Federal Food and Drug Administration. J Am Acad Orthop Surg 16: 241-242 [Full Text]  
• Greenspan, H., Picca, S. M., Sonder, G. (2008). A Pivotal Medical-Device Case. NEJM 358: 1758-1758 [Full Text]